Clinical News

2023-05-22

Early efficacy and safety of BI907828 in MDM2-amplified dedifferentiated liposarcoma (DDLPS)

In a phase 1 trial, the oral MDM2/p53 antagonist, BI907828, demonstrated preliminary antitumor capability & manageable safety in dedifferentiated liposarcoma (DDLPS). This data was also presented at 2023 ESMO Sarcoma and Rare Cancers Congress.

2023-05-22

Pemigatinib demonstrated preliminary benefit in previously treated patient with solid tumor harbored FGFR alterations

Results from the phase 2 FIGHT-207 trial of the FGFR inhibitor pemigatinib in previously treated advanced/metastatic solid tumors with FGFR alterations were presented at the 2023 AACR Annual Meeting.

2023-04-17

The potential Efficacy of Patritumab Deruxtecan in pretreated EGFRmut NSCLC

Recently, results from the phase 1 trial showed that patients with pretreated EGFR-mutated metastatic or unresectable NSCLC treated with patritumab deruxtecan experienced a ORR of 40.2%. This outcome might provide the patients with more treatment option after frontline therapy.

2023-04-17

Final pre-specified overall survival in the PROpel trial: abiraterone combined with olaparib as first-line therapy for metastatic castration-resistant prostate cancer

The phase III PROpel trial demonstrated promising overall survival results of abiraterone and olaparib combination as first-line treatment of mCRPC

Final pre-specified overall survival in PROpel: abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer (Slide presentation in ASCO GU 2023)

2023-04-17

Phase 1b SOLAR trial: Combination of olaparib and selumetinib demonstrates clinical benefit in solid tumors with RAS pathway activation

The SOLAR trial - PARP inhibitor olaparib combined with the MEK inhibitor selumetinib - was presented at the 2023 Society of Gynecologic Oncology (SGO) Women's Cancer Annual Meeting. The combination therapy showed preliminary efficacy in these RAS pathway mutated solid tumor, especially in ovarian and endometrial cancer.

Shannon N. Westin, presented at Scientific Plenary IV: This Just In! Late-Breaking Abstracts, SGO 2023.

2023-03-17

Negative hyper-selection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

The phase III PARADIGM trial demonstrated that hyper-selected patients with no gene alterations would tend to be more beneficial with panitumumab than bevacizumab regardless of primary tumor sidedness.

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial (Slide presentation in ASCO GI 2023)

2023-03-17

UNITE Study - Identified potential molecular biomarkers of response to Enfortumab Vedotin in advance urothelial cancer

A retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) database was presented at the 2023 ASCO Genitourinary Cancers Symposium. Through the next generation sequencing, the study analyzed several molecular biomarkers to identify the correlation between specific biomarkers and the efficacy of enfortumab vedotin.

2023-03-17

Combination of KRAS G12C inhibitor adagrasib with immune checkpoint inhibitor pembrolizumab showed preliminary efficacy in patients with KRAS G12C-mutated NSCLC

The phase 1b KRYSTAL-1 and phase 2 KRYSTAL-7 studies demonstrated that the combination of adagrasib (the second KRAS G12C inhibitor to receive FDA accelerated approval) and pembrolizumab (an immune checkpoint inhibitor) had antitumor activity in patients with NSCLC.

Pasi A. Jänne presented at ESMO IMMUNO-ONCOLOGY 2022, LBA4. Pasi et al.,N Engl J Med 2022; 387:120-131